TY - JOUR
T1 - Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice
AU - Gu, Z.
AU - Akiyama, K.
AU - Ma, X.
AU - Zhang, H.
AU - Feng, X.
AU - Yao, G.
AU - Hou, Y.
AU - Lu, L.
AU - Gilkeson, G. S.
AU - Silver, R. M.
AU - Zeng, X.
AU - Shi, S.
AU - Sun, L.
PY - 2010/11/1
Y1 - 2010/11/1
N2 - Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, which, despite the advances in immunosuppressive medical therapies, remains potentially fatal in some patients, especially in treatment-refractory patients. This study found that transplantation of umbilical cord mesenchymal stem cells (UC-MSCs) has the same therapeutic effect as transplantation of bone marrow mesenchymal stem cells (BM-MSCs), which has been reported to be efficient in treating SLE-related symptoms in MRL/lpr mice. Multi-treatment (at the 18th, 19th, and 20th weeks of age) of 1 - 106 UC-MSCs was able to decrease the levels of 24-h proteinuria, serum creatinine, and anti-double-stranded DNA (dsDNA) antibody, and the extent of renal injury such as crescent formation in MRL/lpr mice. A lower, but still significant, reduction in these parameters was also observed in mice receiving a single dose of UC-MSCs (at the 18th week). UC-MSCs treatment also inhibited expression of monocyte chemotactic protein-1 (MCP-1) and high-mobility group box 1 (HMGB-1) expression in a similar fashion. UC-MSCs labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE) were found in the lungs and kidneys 1 week post infusion. In addition, after 11 weeks post UC-MSCs infusion, human cells were found in kidney of UC-MSCs-treated mice. These findings indicated that UC-MSCs transplantation might be a potentially promising approach in the treatment of lupus nephritis, possibly by inhibiting MCP-1 and HMGB-1 production. Lupus (2010) 19, 1502-1514.
AB - Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, which, despite the advances in immunosuppressive medical therapies, remains potentially fatal in some patients, especially in treatment-refractory patients. This study found that transplantation of umbilical cord mesenchymal stem cells (UC-MSCs) has the same therapeutic effect as transplantation of bone marrow mesenchymal stem cells (BM-MSCs), which has been reported to be efficient in treating SLE-related symptoms in MRL/lpr mice. Multi-treatment (at the 18th, 19th, and 20th weeks of age) of 1 - 106 UC-MSCs was able to decrease the levels of 24-h proteinuria, serum creatinine, and anti-double-stranded DNA (dsDNA) antibody, and the extent of renal injury such as crescent formation in MRL/lpr mice. A lower, but still significant, reduction in these parameters was also observed in mice receiving a single dose of UC-MSCs (at the 18th week). UC-MSCs treatment also inhibited expression of monocyte chemotactic protein-1 (MCP-1) and high-mobility group box 1 (HMGB-1) expression in a similar fashion. UC-MSCs labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE) were found in the lungs and kidneys 1 week post infusion. In addition, after 11 weeks post UC-MSCs infusion, human cells were found in kidney of UC-MSCs-treated mice. These findings indicated that UC-MSCs transplantation might be a potentially promising approach in the treatment of lupus nephritis, possibly by inhibiting MCP-1 and HMGB-1 production. Lupus (2010) 19, 1502-1514.
KW - high-mobility group box 1
KW - lupus nephritis
KW - monocyte chemotactic protein-1
KW - regulatory T cell
KW - systemic lupus erythematosus
KW - umbilical cord mesenchymal stem cell
UR - http://www.scopus.com/inward/record.url?scp=78649245336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649245336&partnerID=8YFLogxK
U2 - 10.1177/0961203310373782
DO - 10.1177/0961203310373782
M3 - Article
C2 - 20647254
AN - SCOPUS:78649245336
VL - 19
SP - 1502
EP - 1514
JO - Lupus
JF - Lupus
SN - 0961-2033
IS - 13
ER -